Label-free kinetic binding data as a decisive element in drug discovery

Expert Opinion on Drug Discovery

Volumn 1, Issue 5, 2006, Pages 439-446

  Andersson, Karl ^a   Karlsson, Robert ^a   Löfås, Stefan ^a   Franklin, Gary ^a   Häinen, Markku D ^a  

^a BIACORE AB   (Sweden)

Author keywords

ADME; kinetics; QSAR; SAR; scaffold selection; selectivity

Indexed keywords

EID: 58449084255     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.1.5.439     Document Type: Review

References (40)

1. KROGSGAARD M, PRADO N, ADAMS EJ et al.: Evidence that structural rearrangements and/or flexibility during TCR binding can contribute to T cell activation. Mol. Cell (2003) 12(6):1367-1378.
2. SWINNEY DC: Biochemical mechanisms of drug action: what does it take for success? Nat. Rev. Drug Discov. (2004) 3(9):801-808.
3. ELG M, GUSTAFSSON D, DEINUM J: The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis. Thromb. Haemost. (1997) 78(4):1286-1292.
4. MARKGREN P-O, SCHAAL W, HAMALAINEN MD et al.: Relationships between structure and interaction kinetics for HIV-1 protease inhibitors. J. Med. Chem. (2002) 45(25):5430-5439.
5. HUBER W: A new strategy for improved secondary screening and lead optimization using high-resolution SPR characterization of compound-target interactions. J. Mol. Recognit. (2005) 18(4):273-281.
6. RICH RL, HOTH LR, GEOGHEGAN KF: Kinetic analysis of estrogen receptor/ligand interactions Proc. Natl. Acad. Sci. USA (2002) 99(13):8562-8567.
7. LOFAS S: Optimizing the hit-to-lead process using SPR analysis. Assay Drug Dev. Technol. (2004) 2(4):1-9.
8. FESSEY RE, AUSTIN RP, BARTON P, DAVIS AM, WENLOCK MC: The role of plasma protein binding in drug discovery, in pharmacokinetic profiling. In: Drug Research. Testa B, Krämer SD, Wunderli-Allenspach H and Folkers G (Eds), Verlag Helvetica Chimica Acta, Zurich, Switzerland (2006).
9. JONES RB, GORDUS A, KRALL JA, MACBEATH G: A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature (2006) 439(7073):168-174.
10. KARLSSON R: SPR for molecular interaction analysis: a review of emerging application areas. J. Mol. Recognit. (2004) 17(3):151-161.
11. CANNON MJ, PAPALIA GA, NAVRATILOVA I et al.: Comparative analyses of a small molecule/enzyme interaction by multiple users of Biacore technology. Anal. Biochem. (2004) 330(1):98-113.
12. TAYLOR P: Drug molecule interactions: mechanism of ligand interactions with carbonic anhydrase studied by magnetic resonance relaxation and rapid reaction methods. J. Pharm. Sci. (1975) 64(3):501-507.
13. COOPER MA: Label-free screening of bio-molecular interactions. Anal. Bioanal. Chem. (2003) 377(5):834-842.
14. DAY YSN, BAIRD CL, RICH RL, MYSZKA DG: Direct comparison of binding equilibrium, thermodynamic, and rate constants determined by surface- and solution-based biophysical methods. Protein Sci. (2002) 11(5):1017-1125.
15. LUNDQVIST T: The devil is still in details - driving early drug discovery forward with biophysical experimental methods. Curr. Opin. Drug Discov. Devel. (2004) 8(4):513-519.
16. HUXLEY P, SUTTON DH, DEBNAM P et al.: High-affinity small molecule inhibitors of T cell costimulation: Compounds for immunotherapy. Chem. Biol. (2004) 11(12):1651-1658.
17. HANSEL TT, BARNES PJ: Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD Drugs Today (Barc) (2002) 38(9):585-600.
18. HALL S, STRICHARTZ G, MOCZYDLOWSKI E, RAVINDRAN A, REICHARRDT PB: The saxitoxins: sources, chemistry, and pharmacology. In: Marine Toxins Origin, Structure and Molecular Pharmacology. Hall S, Strichartz G (Eds.), ACS Symposium Series. American Chemical Society: Washington DC, USA (1990):29-65.
19. ANDERSSON K, CHOULIER L, HÄMÄLÄINEN MD, VAN REGENMORTEL MH, ALTSCHUH D, MALMQVIST M, Predicting the kinetics of peptide-antibody interactions using a multivariate experimental design of sequence and chemical space. J. Mol. Recognit. (2001) 14(1):62-71.
20. SCHAAL W: Computational studies of HIV-1 protease inhibitors. Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy (2002) ISBN: 91-554-5213-2.
21. HELLBERG S, SJSTRM M, SKAGERBERG B, WOLD S: Peptide quantitative structure-activity relationships, a multivariate approach. J. Med. Chem. (1987) 30(7):1126-1135.
22. DELEAGE G, ROUX B: An algorithm for protein secondary structure based on class prediction. Protein Eng. (1987) 1(4):289-294.
23. CHOULIER L, ANDERSSON K, HAMALAINEN MD, VAN REGENMORTEL MH, MALMQVIST M, ALTSCHUH D: QSAR studies applied to the prediction of antigen-antibody interaction kinetics as measured by BIACORE. Protein Eng. (2002) 15(5):373-382.
24. FREYHULT EK, ANDERSSON K, GUSTAFSSON MG: Structural modeling extends QSAR analysis of antibody-lysozyme interactions to 3D-QSAR. Biophys. J. (2003) 84(4):2264-2272.
25. DE GENST E, ARESKOUG D, DECANNIERE K, MUYLDERMANS S, ANDERSSON K: Kinetic and affinity predictions of a protein-protein interaction using multivariate experimental design. JBC (2002) 277(33):29897-29907.
26. TODD MJ, FREIRE E: The effect of inhibitor binding to the structural stability and cooperativity of HIV-1 protease, Proteins (1999) 36(2):147-156.
27. SHUMAN CF, HAMALAINEN MD, DANIELSON UH: Kinetic and thermodynamic characterization of HIV-1 protease inhibitors. J. Mol. Recognit. (2004) 17(2):106-119.
28. PARK BW, ZHANG HT, WU C et al.: Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. Nat. Biotechnol. (2000) 18(2):194-198.
29. BEREZOV A, ZHANG HT, GREENE MI, MURALI R: Disabling erbB receptors with rationally designed exocyclic mimetics of antibodies: structure-function analysis. J. Med. Chem. (2001) 44(16):2565-2574.
30. ABDICHE YN, MYSZKA DG: Probing the mechanism of drug/lipid membrane interactions using Biacore. Anal. Biochem. (2004) 328(2):233-243.
31. KIM K, CHO S, PARK JH et al.: Surface plasmon resonance studies of the direct interaction between a drug/intestinal brush border membrane. Pharm. Res. (2004) 21(7):1233-1239.
32. FROSTELL-KARLSSON A, WIDEGREN H, GREEN CE et al.: Biosensor analysis of the interaction between drug compounds and liposomes of different properties; a two-dimensional characterization tool for estimation of membrane absorption. J. Pharm. Sci. (2005) 94(1):25-37.
33. FROSTELL-KARLSSON A, REMAEUS A, ROOS H et al.: Biosensor analysis of the interaction between immobilized human serum albumin and drug compounds for prediction of human serum albumin binding levels. J. Med. Chem. (2000) 43(10):1986-1992.
34. DAY YS, MYSZKA DG: Characterizing a drugs primary binding site on albumin. J. Pharm. Sci. (2003) 92(2):333-343.
35. NÄSLUND A, BJORKELUND H, STENBERG J, ANDERSSON K, FRANKLIN G: Rapid, reproducible screening of drug compound-target protein interactions using Biacore A100. Nature Methods Application Notes (2006):14-16.
36. ARTURSSON P, PALM K, LUTHMAN K: Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev. (2001) 46(1-3):27-43.
37. KANSY M, SENNER F, GUBERNATOR K: Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J. Med. Chem. (1998) (7):1007-1010.
38. BANKER MJ, CLARK TH, WILLIAMS JA: Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J. Pharm. Sci. (2003) 92(5):967-974.
39. BERTUCCI C, DOMENICI E: Reversible and covalent binding of drugs to human serum albumin: methodological approaches and physiological relevance. Curr. Med. Chem. (2002) 9(15):1463-1481.
40. ANDERSSON K, HAMALAINEN MD: Replacing affinity with binding kinetics in QSAR studies resolves otherwise confounded effects. J. Chemom. (In Press). 101 http://www.biacore.com http Scaffold-class analysis of lead compounds by SPR using a combination of screening and kinetic characterization, application note 26 [BR-9003-47] Available from Biacore AB. (2004).